Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q16795
UPID:
NDUA9_HUMAN
Alternative names:
Complex I-39kD; NADH-ubiquinone oxidoreductase 39 kDa subunit
Alternative UPACC:
Q16795; Q14076; Q2NKX0
Background:
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 9, mitochondrial, also known as Complex I-39kD or NADH-ubiquinone oxidoreductase 39 kDa subunit, plays a crucial role in cellular energy production. It serves as an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), essential for proper complex I assembly and electron transfer from NADH to the respiratory chain, with ubiquinone as the immediate electron acceptor.
Therapeutic significance:
The protein is implicated in Mitochondrial complex I deficiency, nuclear type 26, a condition with autosomal recessive inheritance affecting 1 in 5-10000 live births, leading to a spectrum of disorders from lethal neonatal disease to adult-onset neurodegenerative disorders. Understanding the role of this protein could open doors to potential therapeutic strategies for these conditions.